metricas
covid
Buscar en
Revista Española de Cirugía Ortopédica y Traumatología (English Edition)
Toda la web
Inicio Revista Española de Cirugía Ortopédica y Traumatología (English Edition) A review of difficult-to-treat post-traumatic osteomyelitis: Role of Clostridium...
Información de la revista
Vol. 64. Núm. 4.
Páginas 281-285 (julio - agosto 2020)
Visitas
2596
Vol. 64. Núm. 4.
Páginas 281-285 (julio - agosto 2020)
Original Article
Acceso a texto completo
A review of difficult-to-treat post-traumatic osteomyelitis: Role of Clostridium celerecrescens
Osteomielitis postraumática difícil de tratar: Papel de Clostridium celerecrescens
Visitas
2596
S. Mormeneo Bayoa,
Autor para correspondencia
samorbayo@hotmail.com

Corresponding author.
, I. Ferrer Ceróna, P. Martín Justeb, J. Lallana Duplab, M.I. Millán Loua, J.M. García-Lechuz Moyaa
a Servicio de Microbiología, Hospital Universitario Miguel Servet, Zaragoza, Spain
b Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario Miguel Servet, Zaragoza, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Summary of the 4 cases published in the literature related to Clostridium celerecrescens.
Abstract
Purpose

We reviewed the clinical features of post-traumatic infections produced by Clostri-dium celerecrescens reported in the literature. C. celerecrescens is an emerging pathogen involved in traumatic wound infection that progresses to deep infection and osteomyelitis.

Methods

We found only 4 cases reported in the literature with enough data to be analysed and we added our own case and experience with this type of infection. The identification was performed by matrix-assisted desorption ionization-time of flight mass spectrometry (MALDI TOF) or API Gallery, and 16S rRNA gene sequencing were performed to confirm identification in all cases.

Results

Identification of the bacteria is discrepant according to the method used due to the genetic and phenotypic similarities of other species of the genus. Identification through MALDI-TOF and API gallery is not suitable for determining the specie, confirmation by 16S rRNA sequencing being necessary. Treatment of the infection included complex antibiotic combinations and surgical treatment together with skin and soft tissue dressings due to the persistence of the pathogen over time.

Conclusion

This report supports the pathogenic role of C. celerecrescens in post-traumatic infections and the need to improve the management of these difficult-to-treat infections.

Keywords:
Clostridium celerecrescens
Post-traumatic osteomyelitis
Long bone
Wound
Resumen
Objetivo

Se ha realizado una revisión sobre las infecciones producidas por Clostridium celerecrescens que aparecen recogidas en la literatura. C. celerecrescens es un patógeno emergente relacionado con infecciones de heridas traumáticas que progresan a infecciones profundas y osteomielitis.

Método

En la literatura sólo se han encontrado 4 casos con suficientes datos para ser analizados; nosotros añadimos un nuevo caso y experiencia en el manejo de la infección. La identificación se realizó mediante espectrometría desorción/ionización láser asistida por matriz acoplada a un detector de tiempo de vuelo (MALDI-TOF) o mediante Galería API. Se realizó secuenciación del 16S rRNA en todos los casos.

Resultados

La identificación de la bacteria fue discrepante según el método utilizado debido a las similitud fenotípica y genética con otras especies del mismo género. La identificación mediante MALDI-TOF y Galerías API no resulta adecuada para la determinación a nivel de especie, siendo necesaria la secuenciación del ARNr 16S. El tratamiento de la infección incluye combinaciones de antibióticos complejas y tratamiento quirúrgico junto con curas de piel y partes blandas debido a la persistencia de la bacteria a lo largo del tiempo.

Conclusión

El presente estudio manifiesta el potencial patogénico de C. celerecrescens en infecciones postraumáticas y la necesidad de mejorar el manejo de estas infecciones.

Palabras clave:
Clostridium celerecrescens
Osteomielitis postraumática
Hueso largo
Herida
Texto completo
Introduction

The origin of post-traumatic osteomyelitis is the result of trauma or a nosocomial infection after trauma treatment, where pathogens reach the bone, proliferate in the damaged tissue and cause bone infection. Implants or open fractures favour the entry of anaerobes and gram-negative bacilli. Persistent bone infection favours chronic, often polymicrobial, osteomyelitis. Although all bones can be involved, osteomyelitis mainly occurs in the lower limbs. Appropriate therapy should include drainage and debridement of the site accompanied by antibiotic treatment, which in most cases can be based on the microbiological result.1

The Clostridium genus is formed by a heterogeneous group of sporulated gram-positive bacilli that are present in the environment and colonise the intestinal tract of mammals.2 The genus comprises over 220 species of strict anaerobes (some of which may be aerotolerant), but only a few are considered clinically relevant.3 Due to the large number of species in the genus, some Clostridium spp. may not be correctly identified. This is the case with Clostridium celerecrescens, a species that shares the same biochemical properties and sensitivity of other species of the Clostridium genus.2,4,5 The first case of C. celerecrescens was published in 1989 and isolated from cow dung in a methanogenic cellulose-enriched culture. The microorganism was given its name due to its rapid growth.6

To date, more than 800 cases of bone infections caused by anaerobes over the last 50 years have been published. In fact, the Clostridium genus is involved in many cases of long bone infections.7 Only 4 articles have been published to date on osteomyelitis caused by C. celerecrescens; there was a history of post-traumatic bone fracture in all cases. We present a new case and a review of the published cases, with the aim of appropriately identifying and managing osteomyelitis caused by C. celerecrescens.

Material and methods

A search was conducted from 1980 onwards for all articles in English and Spanish in which the keywords Clostridium celerecrescens and/or Clostridium sphenoides appeared.

Identification was carried out by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF) or API gallery. 16S rRNA sequencing was performed in all cases. Mass sequencing was performed in one case.8

The minimum inhibitory concentration was determined by E-test of anaerobes in all cases. In our case, the interpretation of the minimum inhibitory concentration was made according to the criteria for gram-positive anaerobes of the European Society for Clinical Microbiology and Infectious Diseases (EUCAST 2016/2017)

Results

We found 4 cases in the literature and we add a further case with similar characteristics to the published cases. These articles’ references are shown and summarised in Table 1.

Table 1.

Summary of the 4 cases published in the literature related to Clostridium celerecrescens.

Reference  Age/sex Underlying disease  Source  Microbiological findings  MIC (μg/mL)  Antibiotic treatment  Result 
Perkins et al.8  20/H. None  Grade II fracture of right radius and ulna  C. sphenoides (MALDI), C. celerecrescens (16S rRNA) and C. sphenoides (SM)  Penicillin = 3  1. Trimethoprim-sulfamethoxazole, cephalexin, and Clindamycin (with no improvement)  Cure 
        Piperacillin (only if specified as S)  2. Vancomycin and ampicillin/sulbactam   
        Vancomycin = 1.5  3. Daptomycin and Piperacillin/tazobactam   
        Daptomycin = .25  4. Ampicillin/sulbactam (6 weeks)   
        Clindamycin>256  5. Amoxycillin-clavulanic acid (3 months)   
        Metronidazole (only if specified as S)     
Mischnik et al.3  55/M. DM, PAD, alcoholism  In 2000, grade iii open fracture of tibia  2000: spore-forming bacteria (with no more information)  Amoxycillin-clavulanic acid = 2  2009:  Cure 
      2001: MSSA  Clindamycin = 2  1. Cefuroxime iv (1500 mg 3 times/day)+ Metronidazole iv (400 mg 3 times/day) for 15 days   
      Following 8 years with no symptoms  Imipenem = 2  2. Topical clindamycin   
      2009 and 2010: C. clostridioforme (API), C. sphenoides (MALDI-TOF) and C. celerecrescens (16S rRNA)  Metronidazole=.06  3. Non-specific oral therapy for 6 weeks   
          2010:   
          Cefuroxime (1500 mg, 3 times/day)+Metronidazole (400 mg, 3 times/ day)   
Bouvet et al.2  20/H. None  Traumatic wound chopping wood  C. clostridioforme (rapid 32A strips) and C. celerecrescens (16S rRNA)  Amoxycillin-clavulanic acid = .75  1g amoxycillin + clavulanic acid, 3 times/day for 7 days  Cure 
        Moxifloxacin = .38     
        Vancomycin = 1.5     
Glazunova et al.9  45/H  Open femur fracture after a fall  First Enterobacter cloacae was isolated. One month later, Eubacterium limosum was identified with the API-20A galleriesIdentified as C. celerecrescens by 16S rRNA testing  Not specified  Ciprofloxacin (500mg × 3, 3 times /day) and ceftriaxone (2 g/day) for E. cloacaeSulfamethoxazole (800mg × 6/day), trimethoprim (160mg × 6/day), Clindamycin (600mg × 2/day) and Metronidazole (250mg × 2/day) for C. celerecrescens  Cure 

MIC: minimum inhibitory concentration; DM: diabetes mellitus; PAD: peripheral artery disease; iv: intravenous; MSSA: Methicillin-sensitive Staphylococcus aureus; MS: massive sequencing.

We present the case of a 39-year-old women with no underlying disease who was involved in a car accident in 2016 and whose main injuries were an open, bilateral diaphyseal femur fracture and multiple rib fractures. After initial stabilisation, the patient underwent emergency surgery in another centre, with reduction and intramedullary nailing of both femur fractures. She made satisfactory progress in the immediate postoperative period and was discharged from hospital.

In September 2016, the patient attended our centre’s emergency department with an abscess in her right thigh that required draining in the operating theatre. Intra-operative cultures of Lelliottia amnigena and Clostridium spp. were isolated. Therefore, given these findings, we decided to re-operate and perform debridement, copious flushing, and antibiotic treatment. On completion of the antibiotic treatment, the L. amnigena was eradicated. However, Clostridium spp. continued to be isolated in cultures until March 2017 despite different combinations of antibiotics and more than 18 debridements. Fig. 1 shows the patient’s clinical progress along with the prescribed antibiotic treatment.

Figure 1.

Course of disease caused by Clostridium celerecrescens in post-traumatic osteomyelitis.

(0.19MB).

The patient is currently undergoing rehabilitation treatment and needs to use a crutch and a raised insole of 7 mm for the lower left limb due to dysmetria. She has shown no further clinical or analytical signs of infection during follow-up to date and the risk-benefit of a total right knee replacement is being considered.

In the 5 cases, MALDI-TOF identified C. sphenoides and the API gallery Clostridium clostridioforme.

16S rDNA gene sequencing related in all cases to C. celerecrescens. In our case, the 16S rDNA gene was sequenced with primers 16S-F and E533R and related to C. celerecrescens by 99% (QC 100%, Ident 99%) (NCBI accession no. AB 910754.1).

Antibiotic sensitivity, in our case, was: benzylpenicillin = 4, ampicillin≤4, amoxycillin-clavulanic acid≤4/2, piperacillin-tazobactam = 16, imipenem = 8, clindamycin>256, metronidazole≤4 and vancomycin = .5 μg/mL. The minimum inhibitory concentration of the other cases is shown in Table 1. It is worth mentioning that although moxifloxacin showed a good profile against this bacterium, quinolone treatment was not selected as therapy in any of the published cases except the last, where C. celerecrescens was isolated from an abscess

Discussion

Post-traumatic osteomyelitis can be caused by a wide range of microorganisms, such as Aeromonas, Pseudomonas and other enterobacteria, most of which are present in soil, water, and organic detritus.9–11 Therefore in the case of open fractures anaerobic infection must be suspected where Clostridium is particularly relevant. The virulence factors of some of some Clostridium species in bone and soft tissues are not completely known,4,6 but various studies indicate that spore production, different degrees of mobility and the production of enzymes and toxins can cause necrosis and leukocyte lysis.

C. celerecrescens appears in all the cases shown in the literature on post-traumatic osteomyelitis. This bacterium was isolated in different samples and at different times. In fact, in our case, the patient suffered her accident in August 2016 and C. celerecrescens continued to be isolated after more than 7 months, and antibiotic treatment ended in July 2017.

Identification by MALDI-TOF and by the API gallery is not suitable for testing at species level, as they are not able to discriminate between C. sphenoides and C. celerecrescens. In fact, in 2 cases isolation of both genera in the same sample was reported using 2 different methods; identification was subsequently confirmed by 16S rRNA. However, in one case, mass sequencing was inconsistent with 16S rRNA, possibly because the primer used in the 16S rRNA analysis was non-specific. One possible explanation for why the bacterium is rarely isolated from clinical samples may be its phenotypic and genetic similarity to other species in the genus. For this reason, molecular testing is necessary

In the published cases, treatment included complex combinations of antibiotics, in all cases with anaerobic coverage. It is important to highlight that within the C. clostridioforme group, which includes C. celerecrescens, antibiotic resistance is relatively frequent. In our case, the empirical treatment was not adequate due to the choice of carbapenems, in vitro sensitivity to imipenem being intermediate. Despite adjusting the treatment with specific antibiotics, the bacteria could not be eradicated, hyperbaric therapy and dalbavancin treatment were required for more comfortable management of the patient. Further study of a larger number of cases is needed to obtain more representative data on the antibiotic sensitivity of this species.

On the other hand, we must bear in mind that treatment of osteomyelitis must be combined with debridement surgery to control the focus of infection. How surgery will affect the patient’s progress should be considered when evaluating a case.

Similarly, appropriate treatment of the skin and soft tissue is essential for bone tissue recovery. We believe it is relevant to point out that in this case silver-sulfadiazine-impregnated dressings resulted in the best outcome for the patient. This product is widely used in the treatment of other injuries such as burns, but there is no evidence of its use in soft tissue coverage in infectious disease.11

In all cases, the patients made a full recovery, although the bacteria were isolated repeatedly over time.

Intensive surgical treatment, together with skin and soft tissue dressings, is essential. This article supports the pathogenic role of C. celerecrescens in causing rare and difficult-to-treat infections. For this reason, molecular testing is important to identify related species correctly.

Level of evidence

Level of evidence iii.

Conflict of interests

The authors have no conflict of interests to declare.

References
[1]
J.T. Mader, M.W. Cripps, J.H. Calhoun.
Adult posttraumatic osteomyelitis of the tibia.
Clin Orthop Relat Res, (1999), pp. 14-21
[2]
P. Bouvet, G. K’Ouas, A. Le Coustumier, M.R. Popoff.
Clostridium celerecrescens, often misidentified as “Clostridium clostridioforme group,” is involved in rare human infection cases.
Diagn Microbiol Infect Dis, 74 (2012), pp. 299-302
[3]
A. Mischnik, S. Zimmermann, I. Bekeredjian-Ding, M. Egermann.
Relapse of posttraumatic osteomyelitis due to Clostridium celerecrescens.
Infection, 39 (2011), pp. 491-494
[4]
K.C. Carroll, M.A. Pfaller, M.L. Landry, A.J. McAdam, R. Patel, S.S. Richter, et al.
Manual of Clinical Microbiology.
12th edition, ASM Press, (2019),
[5]
T. Steer, M.D. Collins, G.R. Gibson, H. Hippe, P.A. Lawson.
Clostridium hathewayi sp nov., from human feces.
Syst Appl Microbiol, 24 (2001), pp. 353-357
[6]
M.L.L. Palop, S. Valles, F. Piñaga, A. Flors.
Isolation and Characterization of an Anaerobic, Cellulytic Bacterium, Clostridium celerecrescens sp. nov..
Int. J. Syst. Evol. Microbiol, (1989), pp. 68-71
[7]
I. Brook.
Microbiology and management of joint and bone infections due to anaerobic bacteria.
J Orthop Sci, 13 (2008), pp. 160-169
[8]
M.J. Perkins, E. Snesrud, P. McGann, C.A. Duplessis.
Clostridium sphenoides Chronic Osteomyelitis Diagnosed Via Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry, Conflicting With 16S rRNA Sequencing but Confirmed by Whole Genome Sequencing.
Mil Med, 182 (2017), pp. e1669-72
[9]
O. Glazunova, D. Raoult, V. Roux.
First identification of Clostridium celerecrescens in liquid drained from an abscess.
J Clin Microbiol, 43 (2005), pp. 3007-3008
[10]
J.B. Wright, K. Lam, R.E. Burrell.
Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment.
Am J Infect Control, 26 (1998), pp. 572-577
[11]
T.J. Bonatus, A. Herbert.
Posttraumatic Aeromonas hydrophyla osteomyelitis.
Orthopedics, 13 (1990), pp. 1158-1163

Please cite this article as: Mormeneo Bayo S, Ferrer Cerón I, Martín Juste P, Lallana Dupla J, Millán Lou MI, García-Lechuz Moya JM. Osteomielitis postraumática difícil de tratar: papel del Clostridium celerecrescens. Rev Esp Cir Ortop Traumatol. 2020;64:281–285.

Copyright © 2020. SECOT
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos